Abstract
The challenge for treating breast cancer (BC) is partly due to long-term dormancy driven by formation of cancer stem cells (CSCs) capable of evading immune response and resist chemotherapy. BC cells (BCCs) show preference for bone marrow (BM), resulting in poor prognosis. CSCs utilize connexin 43 (Cx43) to form gap junctional intercellular communication (GJIC) with BM niche cells, fibroblasts and mesenchymal stem cells (MSCs). However, Cx43 is an unlikely target to reverse BC dormancy due to its role as hematopoietic regulator. We found N-cadherin (CDH2) and its associated pathways as potential drug targets. CDH2, highly expressed in CSCs, interacts intracellularly with Cx43, co-localizes with Cx43 in BCCs within BM biopsies of patients, and is required for Cx43-mediated GJIC with BM niche cells. Notably, CDH2-associated γ-secretase and pro-apoptotic pathways maintained BC dormancy. We thereby propose these pathways as potential pharmacological targets to prevent dormancy and chemosensitize resistant CSCs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
